Mark J Enyedy
CIK 1586965 · CHIEF EXECUTIVE OFFICER · last filed 2026-06-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.01M
Companies
7
Total Filings
47
Lifetime Open-Market Net
-$52.99M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BMRN | Director | 21,040 | $63.81 | $1.34M | $0 | 4 | 2026-06-04 |
| CRL | Director | 2,384 | $267.49 | $637.7K | $0 | 2 | 2026-05-11 |
| ImmunoGen, Inc. (IMGN) Delisted | CHIEF EXECUTIVE OFFICER | 0 | $31.23 | $0 | -$52.99M | 22 | 2024-02-12 |
| LogicBio Therapeutics, Inc. (LOGC) Delisted | Director | 0 | $7.06 | $0 | $0 | 6 | 2022-11-17 |
| AKBA | Director | 31,143 | $0.91 | $28.3K | $0 | 3 | 2020-06-09 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Director | 0 | — | — | $0 | 3 | 2018-12-13 |
| FATE | Director | — | $2.80 | — | $0 | 3 | 2017-05-04 |
Recent Filings · Page 5 of 5
47 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-02-20 | ImmunoGen, Inc. (IMGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-09-13 | KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-05-04 | FATE | Grant (A) | — | $0 | EDGAR |
| 2017-02-23 | ImmunoGen, Inc. (IMGN) Delisted | Grant (A) | +500,000 | $1.24M | EDGAR |
| 2016-11-09 | ImmunoGen, Inc. (IMGN) Delisted | Buy (P) | +25,000 | $45.7K | EDGAR |
| 2016-05-13 | FATE | Grant (A) | — | $0 | EDGAR |
| 2015-05-15 | FATE | Grant (A) | — | $0 | EDGAR |
Showing 41–47 of 47
Prev
Page 5 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.